Treat fast but abandon time from ischemic stroke onset as a criterion for treatment: The DAWN and DEFUSE-3 trials
- 5 April 2018
- journal article
- editorial
- Published by SAGE Publications in International Journal of Stroke
- Vol. 13 (4), 344-347
- https://doi.org/10.1177/1747493018769004
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- Shifting bottlenecks in acute stroke treatmentJournal of NeuroInterventional Surgery, 2015
- Randomized Assessment of Rapid Endovascular Treatment of Ischemic StrokeNew England Journal of Medicine, 2015
- Good is not Good Enough: The Benchmark Stroke Door-to-Needle Time Should be 30 MinutesCanadian Journal of Neurological Sciences, 2014
- Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trialsThe Lancet, 2014
- Stroke- on- Awakening: Safety of CT-CTA Based Selection for Reperfusion TherapyCanadian Journal of Neurological Sciences, 2014
- Tissue Window in Stroke Thrombolysis Study (TWIST): A Safety StudyCanadian Journal of Neurological Sciences, 2013
- The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trialThe Lancet, 2012
- Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysisThe Lancet, 2012
- Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic StrokeNew England Journal of Medicine, 2008
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995